Middle East & Africa Molecular Diagnostics for Infectious Disease Market Forecast to 2030
Middle East & Africa Molecular Diagnostics for Infectious Disease Market Forecast to 2030 – Regional Analysis – by Type (Point-of-Care Testing and Laboratory Testing), End User [Point-of-Care Testing (Human Testing and Vet Testing) and Laboratory Testing (Human Testing and Vet Testing)], Application [Point-of-Care Testing (Detection of Single Pathogen, Detection of Two or More Pathogens, Evaluation of Emerging Novel Infections, Surveillance and Early Detection of Biothreat Agents and Diseases-Related Biomarker, and Antimicrobial Resistance Profiling) and Laboratory Testing (Patient stratification, Drug Regimen Selection, Toxicity Avoidance, Therapeutic Monitoring, and Detection of Predisposition to Disease)], Disease Type [Point-of-Care Testing (Sepsis, Prosthetic Joint Infection (PJI), Endocarditis, STDs, Mononucleosis, Group A Streptococcus (GAS), and Others) and Laboratory Testing (Sepsis, Prosthetic Joint Infection (PJI), Endocarditis, STDs, Chlamydia, Gastrointestinal Infection, Tuberculosis, H1N1 Virus, and Others)], Infection Type [Point-of-Care Testing (Bacteria, Viral, Fungi, and Others) and Laboratory Testing (Bacteria, Viral, Fungi, and Others)]
$2,485 – $3,885
- Description
- Toplines
- Reasons for Buying
- Table of Contents
- List of Tables
- LIst of Figures
- List of Companies
- Reviews (0)
Description
Molecular Diagnostics for Infectious Diseases in Personalized Medicine Fuels the Middle East & Africa Molecular Diagnostics for Infectious Disease Market
Genome research has become more convenient and cost-effective with progress in high-throughput techniques. Molecular diagnostics is becoming increasingly indispensable in clinical laboratories as these kits and tests provide rapid detection results as opposed to conventional tests, which involve culturing microbes in laboratory conditions in a few cases. Medical treatments and interventions are tailored to each patient using precision medicine based on their unique genetic makeup, lifestyle, and environment. Molecular diagnostics plays an important role in this approach, as it enables the identification of specific biomarkers, genetic mutations, and gene expression patterns that impact decision-making related to the treatment of patients. Drug development has become increasingly dependent on molecular diagnostics. Various molecular imaging techniques are used in screening, detecting, diagnosing, treating, and assessing heterogeneity to make progression plans, examine molecular characteristics, and monitor patient outcomes. Personalized medicine generally aims to interrogate the genomic information of a patient, e.g., drug metabolism polymorphisms help guide drug choice and dosage. In infectious diseases, personalized medicine concepts can be used to rapidly identify disease-causing microorganisms, determine their antimicrobial resistance profiles, and ascertain an appropriate antimicrobial treatment for the proper management of the patient based on the results. Point-of-care testing for infectious diseases requires the acceptance of medical authorities, development of new technology and communication platforms, and reimbursement policies so that the greatest number of patients can benefit from lifesaving and time-saving procedures. Introducing these techniques into clinical practice would enable the identification of molecular targets in each patient, along with facilitating the tracking of the molecular progression of diseases.
Thus, with ever-evolving technology, the market for molecular diagnostics for infectious diseases seems to have a bright future.
Middle East & Africa Molecular Diagnostics for Infectious Disease Market Overview
The UAE, Saudi Arabia, and South Africa are major countries in the Middle East & Africa. The market in the Middle East & Africa is anticipated to grow during 2022-2030 due to the rising prevalence of various infectious diseases, and conducive environment created by government initiatives in terms of funding and healthcare-related policies. In March 2023, Mylab Discovery Solutions, one of the leading biotech companies in India, announced an exclusive strategic partnership with AstraGene LLC, the first molecular manufacturing company in the UAE, to develop automated molecular diagnostics solutions for markets in the UAE and Kuwait. Under the agreement, Mylab and AstraGene would codevelop molecular diagnostic solutions such as reagents, kits, and fully automated devices. This partnership marks Mylab’s latest international market expansion and supports the company’s long-term growth strategy to make high-quality diagnostics accessible to customers across the world. Such strategic initiatives taken by market players for the introduction of novel solutions in the Middle East & Africa are fueling the growth of the molecular diagnostic for infectious disease market.
Middle East & Africa Molecular Diagnostics for Infectious Disease Market Revenue and Forecast to 2030 (US$ Million)
Middle East & Africa Molecular Diagnostics for Infectious Disease Market Segmentation
The Middle East & Africa molecular diagnostics for infectious disease market is segmented based on type, end user, application, disease type, infection type, and country.
Based on type, the Middle East & Africa molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. The laboratory testing segment held a larger Middle East & Africa molecular diagnostics market for infectious disease market share in 2022.
The Middle East & Africa molecular diagnostics for infectious disease market, by end user, is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further bifurcated into human testing and vet testing. Similarly, laboratory testing is further bifurcated into human testing and vet testing. The human testing segment, by point-of-care testing, held a larger Middle East & Africa molecular diagnostics market for infectious disease market share in 2022. Additionally, the human testing segment, by laboratory testing, held a larger Middle East & Africa molecular diagnostics market for infectious disease market share in 2022.
Based on application, the Middle East & Africa molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into detection of single pathogen, detection of two or more pathogens, evaluation of emerging novel infections, surveillance and early detection of biothreat agents and diseases-related biomarker, and antimicrobial resistance profiling. Similarly, laboratory testing is further categorized into patient stratification, drug regimen selection, toxicity avoidance, therapeutic monitoring, and detection of predisposition to disease. The detection of a single pathogen segment, by point-of-care testing, held the largest Middle East & Africa molecular diagnostics for infectious disease market share in 2022. Additionally, the drug regimen selection segment, by laboratory testing, held the largest Middle East & Africa molecular diagnostics for infectious disease market share in 2022.
Based on disease type, the Middle East & Africa molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into sepsis (e.g. urogenital/lung/wound), prosthetic joint infection, endocarditis, STDs, mononucleosis, group A streptococcus, and others. Similarly, laboratory testing is further categorized into sepsis, prosthetic joint infection, endocarditis, STDs, chlamydia, gastrointestinal infection, tuberculosis, H1N1 virus, and others. The STDs segment, by point-of-care testing, held the largest Middle East & Africa molecular diagnostics for infectious disease market share in 2022. Additionally, the STDs segment, by laboratory testing, held the largest Middle East & Africa molecular diagnostics for infectious disease market share in 2022.
Based on infection type, the Middle East & Africa molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. The Point-of-care testing is further segmented into bacteria, viral, fungi, and others. Similarly, laboratory testing is further categorized into bacteria, viral, fungi, and others. The bacteria segment, by point-of-care testing, held the largest Middle East & Africa molecular diagnostics for infectious disease market share in 2022. Additionally, the bacteria segment, by laboratory testing, held the largest Middle East & Africa molecular diagnostics for infectious disease market share in 2022.
Based on country, the Middle East & Africa molecular diagnostics for infectious disease market is categorized into Saudi Arabia, the UAE, South Africa, and the Rest of Middle East & Africa. Saudi Arabia dominated the Middle East & Africa molecular diagnostics for infectious disease market in 2022.
F. Hoffmann-La Roche Ltd, Abbott Laboratories, Thermo Fisher Scientific Inc, bioMerieux SA, Danaher Corp, Hologic Inc, Siemens Healthineers AG, Bruker Corp, and DiaSorin SpA are some of the leading companies operating in the Middle East & Africa molecular diagnostics for infectious disease market.
Summary Info
| Industry: | |
|---|---|
| Pricing options: | |
| Geographical coverage: | |
| Year of Publication: |
According to the Research Team’ research, the Middle East & Africa molecular diagnostics for infectious disease market was valued at US$ 134.22 million in 2022 and is expected to reach US$ 301.21 million by 2030, registering a CAGR of 10.6% from 2022 to 2030. Rising application of molecular diagnostics in veterinary infectious diseases and surging prevalence of infectious disease globally are among the critical factors attributed to the Middle East & Africa molecular diagnostics for infectious disease market expansion.
Public health is adversely affected by infectious diseases, causing morbidity, mortality, and economic burdens. Infectious diseases are on the rise, necessitating accurate and timely diagnosis to form the basis for effective disease management, treatment, and prevention. Diagnosing and monitoring multiple infections and diseases-including HIV, tuberculosis, hepatitis C, human papillomavirus screening for cervical cancer, and sexually transmitted infections, as well as outbreaks of infections-can be performed using molecular diagnostics techniques, laboratory-based assays, and point-of-care tests. According to an article published in the National Library of Medicine (NLM) in 2021, infectious diseases are a major problem in most African countries due to limited healthcare resources and the high disease burden. More than 200 pathogens can cause fever in Nigeria, one of the most common reasons for visiting a healthcare facility. These pathogens include malaria parasites, Salmonella enterica and hemorrhagic viruses. It is impossible to reliably detect life-threatening pathogens with only culture results. Therefore, efficient molecular diagnostics are essential in areas with high infectious disease burdens.
A resurgence in certain infectious diseases has been observed over the past few years. For instance, the reemergence of diseases such as tuberculosis, malaria, and hepatitis has necessitated the development of effective diagnostic tools to identify the causative agents and determine effective treatment regimens. According to the World Health Organization (WHO), ~10.6 million cases of tuberculosis were reported globally in 2021, which is equivalent to 134 cases per 100,000 people. TB cases are reported as follows in countries such as. In 2021, four countries recorded malaria deaths as follows: Nigeria (31%), the Democratic Republic of the Congo (13%), Niger (4%), and Tanzania (4%). According to the WHO African Region’s estimates, there were roughly 40 million pregnancies in 38 moderate and high transmission countries in 2021, of which 13.3 million (32%) contracted malaria during pregnancy. Thus, the surging prevalence of infectious disease propels the need for molecular diagnostic technology over traditional techniques, such as microbial culture, hemagglutination inhibition tests, and enzyme-linked immunosorbent assays (ELISA).
On the contrary, limitations associated with molecular testing hampers the growth Middle East & Africa molecular diagnostics for infectious disease market.
Based on type, the Middle East & Africa molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. The laboratory testing segment held 59.0% share of Middle East & Africa molecular diagnostics for infectious disease market in 2022, amassing US$ 79.24 million. It is projected to garner US$ 174.19 million by 2030 to expand at 10.3% CAGR during 2022-2030.
The Middle East & Africa molecular diagnostics for infectious disease market, by end user, is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further bifurcated into human testing and vet testing. Similarly, laboratory testing is further bifurcated into human testing and vet testing. The human testing segment, by point-of-care testing, held 95.7% share of the Middle East & Africa molecular diagnostics for infectious disease market in 2022, amassing US$ 52.61 million. It is projected to garner US$ 120.66 million by 2030 to expand at 10.9% CAGR during 2022-2030. Additionally, the human testing segment, by laboratory testing, held 95.1% share of the Middle East & Africa molecular diagnostics for infectious disease market in 2022, amassing US$ 75.36 million. It is projected to garner US$ 164.48 million by 2030 to expand at 10.2% CAGR during 2022-2030.
Based on application, the Middle East & Africa molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into detection of single pathogen, detection of two or more pathogens, evaluation of emerging novel infections, surveillance and early detection of biothreat agents and diseases-related biomarker, and antimicrobial resistance profiling. Similarly, laboratory testing is further categorized into patient stratification, drug regimen selection, toxicity avoidance, therapeutic monitoring, and detection of predisposition to disease. The detection of a single pathogen segment, by point-of-care testing, held 45.3% share of the Middle East & Africa molecular diagnostics for infectious disease market in 2022, amassing US$ 24.88 million. It is projected to garner US$ 56.24 million by 2030 to expand at 10.7% CAGR during 2022-2030. Additionally, the drug regimen selection segment, by laboratory testing, held 36.6% share of the Middle East & Africa molecular diagnostics for infectious disease market in 2022, amassing US$ 28.97 million. It is projected to garner US$ 63.41 million by 2030 to expand at 10.3% CAGR during 2022-2030.
Based on disease type, the Middle East & Africa molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into sepsis (e.g. urogenital/lung/wound), prosthetic joint infection, endocarditis, STDs, mononucleosis, group A streptococcus, and others. Similarly, laboratory testing is further categorized into sepsis, prosthetic joint infection, endocarditis, STDs, chlamydia, gastrointestinal infection, tuberculosis, H1N1 virus, and others. The STDs segment, by point-of-care testing, held 65.3% share of the Middle East & Africa molecular diagnostics for infectious disease market in 2022, amassing US$ 35.91 million. It is projected to garner US$ 84.49 million by 2030 to expand at 11.3% CAGR during 2022-2030. Additionally, the STDs segment, by laboratory testing, held 54.0% share of the Middle East & Africa molecular diagnostics for infectious disease market in 2022, amassing US$ 42.76 million. It is projected to garner US$ 96.24 million by 2030 to expand at 10.7% CAGR during 2022-2030.
Based on infection type, the Middle East & Africa molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. The Point-of-care testing is further segmented into bacteria, viral, fungi, and others. Similarly, laboratory testing is further categorized into bacteria, viral, fungi, and others. The bacteria segment, by point-of-care testing, held 47.8% share of the Middle East & Africa molecular diagnostics for infectious disease market in 2022, amassing US$ 26.28 million. It is projected to garner US$ 59.58 million by 2030 to expand at 10.8% CAGR during 2022-2030. Additionally, the bacteria segment, by laboratory testing, held 47.6% share of the Middle East & Africa molecular diagnostics for infectious disease market in 2022, amassing US$ 37.70 million. It is projected to garner US$ 81.35 million by 2030 to expand at 10.1% CAGR during 2022-2030.
Based on country, the Middle East & Africa molecular diagnostics for infectious disease market is categorized into Saudi Arabia, the UAE, South Africa, and the Rest of Middle East & Africa. Saudi Arabia held 46.3% share of Middle East & Africa molecular diagnostics for infectious disease market in 2022, amassing US$ 62.16 million. It is projected to garner US$ 137.54 million by 2030 to expand at 10.4% CAGR during 2022-2030.
Key players operating in the Middle East & Africa molecular diagnostics for infectious disease market are F. Hoffmann-La Roche Ltd, Abbott Laboratories, Thermo Fisher Scientific Inc, bioMerieux SA, Danaher Corp, Hologic Inc, Siemens Healthineers AG, Bruker Corp, and DiaSorin SpA, among others.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in the Middle East & Africa molecular diagnostics for infectious disease market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the molecular diagnostics for infectious disease market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution
TABLE OF CONTENTS
1. Introduction
1.1 the Research Team Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
2.2 Middle East & Africa Molecular Diagnostic for Infectious Diseases Market, by Country, Market attractiveness
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Middle East & Africa Molecular Diagnostic for Infectious Diseases Market – Key Industry Dynamics
4.1 Market Drivers:
4.1.1 Surging Prevalence of Infectious Disease Globally
4.1.2 Rising Application of Molecular Diagnostics in Veterinary Infectious Diseases
4.2 Market Restraints
4.2.1 Limitations Associated with Molecular Testing
4.3 Market Opportunities
4.3.1 Advancements in Molecular Diagnostics Technologies
4.4 Future Trends
4.4.1 Molecular Diagnostics for Infectious Diseases in Personalized Medicine
4.5 Impact Analysis:
5. Molecular Diagnostic for Infectious Diseases Market – Middle East & Africa Market Analysis
5.1 Middle East & Africa Molecular Diagnostic for Infectious Diseases Market Revenue (US$ Mn), 2022 – 2030
6. Middle East & Africa Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 – by Type
6.1 Overview
6.2 Middle East & Africa Molecular Diagnostic for Infectious Diseases Market Revenue Share, by Type, 2022 & 2030 (%)
6.3 Point-of-Care Testing
6.3.1 Overview
6.3.2 Point-of-Care Testing: Middle East & Africa Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 (US$ Million)
6.4 Laboratory Testing
6.4.1 Overview
6.4.2 Laboratory Testing: Middle East & Africa Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 (US$ Million)
7. Middle East & Africa Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 – by End User
7.1 Overview
7.2 Middle East & Africa Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing and Laboratory Testing by End User, 2022 & 2030 (%)
7.2.1 Middle East & Africa Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020-2030 (US$ Million)
7.2.2 Middle East & Africa Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020-2030 (US$ Million)
8. Middle East & Africa Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 – by Application
8.1 Overview
8.2 Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Application, 2022 & 2030 (%)
8.3 Point-of-Care Testing
8.3.1 Overview
8.3.2 Middle East & Africa Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020-2030 (US$ Million)
8.4 Laboratory Testing
8.4.1 Overview
8.4.2 Middle East & Africa: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020-2030 (US$ Million)
9. Middle East & Africa Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 – by Disease Type
9.1 Overview
9.2 Middle East & Africa Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Disease Type, 2022 & 2030 (%)
9.3 Point-of-Care Testing
9.3.1 Overview
9.3.2 Middle East & Africa Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020-2030 (US$ Million)
9.3.2.1 Middle East & Africa Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020-2030 (US$ Million)
9.4 Laboratory Testing
9.4.1 Overview
9.4.2 Middle East & Africa Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020-2030 (US$ Million)
9.4.2.1 Middle East & Africa Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020-2030 (US$ Million)
10. Middle East & Africa Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 – by Infection Type
10.1 Overview
10.2 Middle East & Africa Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Infection Type, 2022 & 2030 (%)
10.3 Point-of-Care Testing
10.3.1 Overview
10.3.2 Middle East & Africa Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020-2030 (US$ Million)
10.4 Laboratory Testing
10.4.1 Overview
10.4.2 Middle East & Africa Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020-2030 (US$ Million)
11. Middle East & Africa Molecular Diagnostic for Infectious Diseases Market – Country Analysis
11.1 Middle East & Africa Molecular Diagnostic for Infectious Diseases Market, Revenue and Forecast to 2030
11.1.1 Overview
11.1.1.1 Middle East & Africa Molecular Diagnostic for Infectious Diseases Market, by Country
11.1.1.2 Saudi Arabia
11.1.1.2.1 Saudi Arabia Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
11.1.1.2.2 Saudi Arabia: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020-2030 (US$ Million)
11.1.1.2.3 Saudi Arabia: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020-2030 (US$ Million)
11.1.1.2.4 Saudi Arabia: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020-2030 (US$ Million)
11.1.1.2.5 Saudi Arabia: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020-2030 (US$ Million)
11.1.1.2.6 Saudi Arabia: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020-2030 (US$ Million)
11.1.1.2.7 Saudi Arabia: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020-2030 (US$ Million)
11.1.1.2.7.1 Saudi Arabia: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020-2030 (US$ Million)
11.1.1.2.8 Saudi Arabia: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020-2030 (US$ Million)
11.1.1.2.8.1 Saudi Arabia: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020-2030 (US$ Million)
11.1.1.2.9 Saudi Arabia: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020-2030 (US$ Million)
11.1.1.2.10 Saudi Arabia: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020-2030 (US$ Million)
11.1.1.3 South Africa
11.1.1.3.1 South Africa Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
11.1.1.3.2 South Africa: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020-2030 (US$ Million)
11.1.1.3.3 South Africa: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020-2030 (US$ Million)
11.1.1.3.4 South Africa: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020-2030 (US$ Million)
11.1.1.3.5 South Africa: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020-2030 (US$ Million)
11.1.1.3.6 South Africa: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020-2030 (US$ Million)
11.1.1.3.7 South Africa: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020-2030 (US$ Million)
11.1.1.3.7.1 South Africa: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020-2030 (US$ Million)
11.1.1.3.8 South Africa: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020-2030 (US$ Million)
11.1.1.3.8.1 South Africa: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020-2030 (US$ Million)
11.1.1.3.9 South Africa: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020-2030 (US$ Million)
11.1.1.3.10 South Africa: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020-2030 (US$ Million)
11.1.1.4 UAE
11.1.1.4.1 UAE Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
11.1.1.4.2 UAE: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020-2030 (US$ Million)
11.1.1.4.3 UAE: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020-2030 (US$ Million)
11.1.1.4.4 UAE: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020-2030 (US$ Million)
11.1.1.4.5 UAE: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020-2030 (US$ Million)
11.1.1.4.6 UAE: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020-2030 (US$ Million)
11.1.1.4.7 UAE: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020-2030 (US$ Million)
11.1.1.4.7.1 UAE: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020-2030 (US$ Million)
11.1.1.4.8 UAE: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020-2030 (US$ Million)
11.1.1.4.8.1 UAE: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020-2030 (US$ Million)
11.1.1.4.9 UAE: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020-2030 (US$ Million)
11.1.1.4.10 UAE: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020-2030 (US$ Million)
11.1.1.5 Rest of Middle East & Africa
11.1.1.5.1 Rest of Middle East & Africa Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
11.1.1.5.2 Rest of Middle East & Africa: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020-2030 (US$ Million)
11.1.1.5.3 Rest of Middle East & Africa: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020-2030 (US$ Million)
11.1.1.5.4 Rest of Middle East & Africa: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020-2030 (US$ Million)
11.1.1.5.5 Rest of Middle East & Africa: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020-2030 (US$ Million)
11.1.1.5.6 Rest of Middle East & Africa: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020-2030 (US$ Million)
11.1.1.5.7 Rest of Middle East & Africa: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020-2030 (US$ Million)
11.1.1.5.7.1 Rest of Middle East & Africa: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020-2030 (US$ Million)
11.1.1.5.8 Rest of Middle East & Africa: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020-2030 (US$ Million)
11.1.1.5.8.1 Rest of Middle East & Africa: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020-2030 (US$ Million)
11.1.1.5.9 Rest of Middle East & Africa: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020-2030 (US$ Million)
11.1.1.5.10 Rest of Middle East & Africa: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020-2030 (US$ Million)
12. Industry Landscape
12.1 Overview
12.2 Growth Strategies Done by the Companies in the Market, (%)
12.3 Organic Developments
12.3.1 Overview
12.4 Inorganic Developments
12.4.1 Overview
13. Company Profiles
13.1 F. Hoffmann-La Roche Ltd
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Abbott Laboratories
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Thermo Fisher Scientific Inc
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 bioMerieux SA
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Danaher Corp
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Hologic Inc
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Siemens Healthineers AG
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Bruker Corp
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 DiaSorin SpA
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
14. Appendix
14.1 About Us
14.2 Glossary of Terms
LIST OF TABLES
Table 1. Middle East & Africa Molecular Diagnostic for Infectious Diseases Market Segmentation
Table 2. Middle East & Africa Molecular Diagnostic for Infectious Diseases Market, for Point of Care Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 3. Middle East & Africa Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 4. Middle East & Africa Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 5. Middle East & Africa Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 6. Middle East & Africa Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 7. Middle East & Africa Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing – Revenue and Forecast to 2030 (US$ Million)
Table 8. Middle East & Africa Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 9. Middle East & Africa Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing – Revenue and Forecast to 2030 (US$ Million)
Table 10. Middle East & Africa Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 11. Middle East & Africa Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 12. Saudi Arabia Molecular Diagnostic for Infectious Diseases Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 13. Saudi Arabia Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 14. Saudi Arabia Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 15. Saudi Arabia Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 16. Saudi Arabia Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 17. Saudi Arabia Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 18. Saudi Arabia Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing – Revenue and Forecast to 2030 (US$ Million)
Table 19. Saudi Arabia Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 20. Saudi Arabia Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing – Revenue and Forecast to 2030 (US$ Million)
Table 21. Saudi Arabia Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 22. Saudi Arabia Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 23. Saudi Arabia Molecular Diagnostic for Infectious Diseases Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 24. South Africa Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 25. South Africa Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 26. South Africa Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 27. South Africa Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 28. South Africa Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 29. South Africa Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing – Revenue and Forecast to 2030 (US$ Million)
Table 30. South Africa Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 31. South Africa Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing – Revenue and Forecast to 2030 (US$ Million)
Table 32. South Africa Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 33. South Africa Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 34. UAE Molecular Diagnostic for Infectious Diseases Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 35. UAE Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 36. UAE Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 37. UAE Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 38. UAE Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 39. UAE Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 40. UAE Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing – Revenue and Forecast to 2030 (US$ Million)
Table 41. UAE Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 42. UAE Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing – Revenue and Forecast to 2030 (US$ Million)
Table 43. UAE Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 44. UAE Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 45. Rest of Middle East & Africa Molecular Diagnostic for Infectious Diseases Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 46. Rest of Middle East & Africa Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 47. Rest of Middle East & Africa Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 48. Rest of Middle East & Africa Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 49. Rest of Middle East & Africa Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 50. Rest of Middle East & Africa Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 51. Rest of Middle East & Africa Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing – Revenue and Forecast to 2030 (US$ Million)
Table 52. Rest of Middle East & Africa Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 53. Rest of Middle East & Africa Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing – Revenue and Forecast to 2030 (US$ Million)
Table 54. Rest of Middle East & Africa Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 55. Rest of Middle East & Africa Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 56. Organic Developments Done By Companies
Table 57. Inorganic Developments Done By Companies
Table 58. Glossary of Terms, Molecular Diagnostic for Infectious Diseases Market
LIST OF FIGURES
Figure 1. Middle East & Africa Molecular Diagnostic for Infectious Diseases Market Segmentation, By Country
Figure 2. Middle East & Africa Molecular Diagnostic for Infectious Diseases Market – Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Middle East & Africa Molecular Diagnostic for Infectious Diseases Market Revenue (US$ Mn), 2022 – 2030
Figure 5. Middle East & Africa Molecular Diagnostic for Infectious Diseases Market Revenue Share, by Type, 2022 & 2030 (%)
Figure 6. Point-of-Testing: Middle East & Africa Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 (US$ Million)
Figure 7. Laboratory Testing: Middle East & Africa Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Middle East & Africa Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing and Laboratory Testing by End User, 2022 & 2030 (%)
Figure 9. Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Application, 2022 & 2030 (%)
Figure 10. Middle East & Africa Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Disease Type, 2022 & 2030 (%)
Figure 11. Middle East & Africa Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Infection Type, 2022 & 2030 (%)
Figure 12. Middle East & Africa Molecular Diagnostic for Infectious Diseases Market, by Key Country – Revenue, 2022 (US$ Million)
Figure 13. Middle East & Africa Molecular Diagnostic for Infectious Diseases Market, By Key Countries, 2022 and 2030 (%)
Figure 14. Saudi Arabia Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 15. South Africa Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 16. UAE Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 17. Rest of Middle East & Africa Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 18. Growth Strategies Done by the Companies in the Market, (%)
The List of Companies – Middle East & Africa Molecular Diagnostics for Infectious Disease Market
1. F. Hoffmann-La Roche Ltd
2. Abbott Laboratories
3. Thermo Fisher Scientific Inc
4. bioMerieux SA
5. Danaher Corp
6. Hologic Inc
7. Siemens Healthineers AG
8. Bruker Corp
9. DiaSorin SpA
You must be logged in to post a review.
Reviews
There are no reviews yet.